A short course of calorie restriction can measurably improve the blood vessels of adults with obesity, but only when moderate to severe obstructive sleep apnea is not in the picture. That is the central finding of a prospective eight-week dietary intervention study conducted in Rio de Janeiro, Brazil, and published in Artery Research. Seventy-six adults aged 40 to 70 years with body mass index between 30 and 40 kg/m2 completed an overnight home sleep test and then followed an energy-restricted diet that cut roughly 800 kcal from each participant’s estimated daily energy expenditure. After eight weeks, both groups had lost similar amounts of weight, yet the vascular rewards of that effort diverged sharply according to sleep apnea severity.
The researchers, led by Samanta Mattos and Mario Fritsch Neves, divided participants using the apnea-hypopnea index measured with a portable WatchPAT-200 device worn overnight at home. Thirty participants fell into the absent-mild category, with fewer than 15 breathing events per hour, while 46 had moderate to severe disease at 15 events per hour or more. Within the full cohort, 9.2 percent had no sleep apnea at all, 30.3 percent had mild disease, 34.2 percent moderate and 26.3 percent severe. This distribution underscores how common the condition is among people with obesity, a population in which it is considered an independent risk factor for cardiovascular comorbidities.
The diet itself was deliberately pragmatic. Total energy value was calculated for each individual by subtracting 800 kcal/day from total daily energy expenditure estimated with Dietary Reference Intake equations based on current body weight. Macronutrients were distributed across conventional ranges, with carbohydrates at 45 to 65 percent of energy, protein at 10 to 35 percent and lipids at 20 to 35 percent. Participants were encouraged to choose unprocessed, local and seasonal foods and to adopt healthy cooking techniques. By the end of the study, 70 participants returned for follow-up; six dropped out, five for lack of interest and one because corticosteroid treatment had begun.
Weight loss was modest and statistically indistinguishable between groups: 3.2 plus or minus 2.3 percent in the absent-mild group versus 3.0 plus or minus 2.7 percent in the moderate-severe group, with a p value of 0.898. Both groups also achieved comparable reductions in body mass index. But the vascular story was different. Only the absent-mild group showed a significant increase in the RR interval, from 879 to 948 milliseconds, a marker of greater parasympathetic influence on heart rhythm. Only that group improved cutaneous vascular conductance during post-occlusive reactive hyperemia, rising from 1.17 to 1.27 APU/mmHg, an index of endothelium-dependent microvascular perfusion measured with laser speckle contrast imaging after three minutes of brachial artery occlusion.
Central hemodynamics told the same selective story. Central systolic pressure fell from 113 to 107 mmHg and pulse wave velocity, a validated oscillometric measure of arterial stiffness, dropped from 6.9 to 6.7 m/s, but only in participants without moderate to severe sleep apnea. Vascular age, estimated from the Framingham Heart Study, also declined significantly only in that group. The moderate-severe group did show a statistically significant reduction in peripheral systolic blood pressure, heart rate, waist circumference and neck circumference after the intervention, and the authors note that both groups achieved roughly a 5 mmHg blood pressure reduction, so weight loss was not without benefit for the more severe group. The distinction lay in the deeper vascular and autonomic measures, which remained unchanged in the moderate-severe participants.
The study also connected these outcomes mechanistically. Changes in cutaneous vascular conductance during reactive hyperemia correlated inversely with changes in both pulse wave velocity and central systolic pressure. When the investigators ran multiple linear regression treating those two vascular endpoints as dependent variables, the association with microvascular improvement held even after adjustment for age and sex. The authors interpret this pattern as consistent with weight loss increasing the bioavailability of nitric oxide and endothelial nitric oxide synthase, thereby improving endothelium-dependent vasodilation, which in turn relates to central pressure and arterial stiffness.
Why would moderate to severe sleep apnea blunt these gains? The authors point to persistent pathophysiology that survives caloric restriction. Sympathetic overactivity, endothelial dysfunction, oxidative stress and systemic inflammation are intensified by sleep apnea and are known to drive deterioration of arterial stiffness over time. Citing prior work, the article notes that sleep apnea is independently associated with reduced endothelial nitric oxide synthase expression, elevated nitrotyrosine as an oxidative stress marker and increased nuclear factor kappa B as an inflammation marker, regardless of adiposity. These derangements persist when the apnea remains untreated, and a study of bariatric surgery patients found that those with sleep apnea showed 2.5 percent less improvement in flow-mediated dilation six months after surgery than patients without it, despite similar weight loss.
Context from other trials reinforces the point that weight loss alone may be insufficient when apnea is significant. A randomized trial of 139 adults with obesity and moderate-to-severe sleep apnea found that 24 weeks of weight loss therapy by itself failed to significantly reduce central systolic pressure or carotid-femoral pulse wave velocity; only weight loss combined with continuous positive airway pressure reduced central systolic pressure. On the other hand, a separate study using the cardio-ankle vascular index reported that three months of weight reduction therapy did improve arterial stiffness, a discrepancy the authors attribute to possible differences in apnea severity, magnitude of weight loss and the method used to measure stiffness.
The findings carry practical weight because they suggest meaningful vascular change can occur at a weight loss level below conventional targets. Guidelines typically indicate that a 5 to 10 percent weight loss is needed for clinically meaningful health benefits, yet this study observed vascular improvements with losses of roughly 3 percent. That aligns with a two-year cohort study reporting blood pressure benefits at weight losses of at least 3 percent but less than 5 percent, and with evidence that reductions in the 3 to 10 percent range associate with a lower ten-year risk of fatal cardiovascular disease. Prior work has also found that weight reduction reduces cardiovascular risk in patients with sleep apnea more effectively than continuous positive airway pressure therapy, reinforcing weight loss as a key strategy in this population.
The authors are careful about limitations. The laser speckle contrast method does not directly assess resistance arteries, though it captures microvascular reactivity associated with early functional changes in cardiovascular disease pathogenesis. The oscillometric pulse wave velocity technique is not the gold standard, although it is validated and widely used in clinical trials. The eight-week duration was short by design and could itself limit the findings, particularly for the moderate-severe group, but the authors argue it was sufficient to reveal benefits in those with less severe or no apnea. Baseline differences also deserve note: the moderate-severe group was older, had higher Framingham risk scores, higher systolic blood pressure and was the only group using statins, although metabolic syndrome prevalence was similar at about half of each group. The conclusion is measured: modest weight loss occurred regardless of apnea severity, but vascular outcomes improved primarily in the absence of moderate or severe obstructive sleep apnea, suggesting that untreated sleep apnea may need to be addressed alongside diet if the full cardiovascular dividend of weight loss is to be realized.
Subject of Research: Whether moderate to severe obstructive sleep apnea blunts the vascular benefits of short-term weight loss in adults with obesity
Article Title: Short-Term Effects of Weight Loss on Microvascular Reactivity and Central Pressure in Adults with Obesity Attenuated by Moderate to Severe Obstructive Sleep Apnea
Article References: Mattos, S., Cunha, M. R., Brum, T., Oigman, W., Klein, M. R. S. T., & Neves, M. F. (2026). Short-Term Effects of Weight Loss on Microvascular Reactivity and Central Pressure in Adults with Obesity Attenuated by Moderate to Severe Obstructive Sleep Apnea. Artery Research, 32(1), Article 36. https://doi.org/10.1007/s44200-026-00132-z
Image Credits: AI Generated
DOI: 10.1007/s44200-026-00132-z
Keywords: obesity, obstructive sleep apnea, weight loss, microvascular reactivity, central blood pressure, arterial stiffness, pulse wave velocity, endothelial function, caloric restriction, heart rate variability, vascular age, Short-Term
News Source: Daisy Hatcher. (October 29, 2026). Weight Loss Improves Vascular Health in Obesity Only When Sleep Apnea Is Mild or Absent. Scienmag.
